Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ARWR NASDAQ:MIRM OTCMKTS:PHGUF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.39-0.2%$17.63$13.50▼$25.67$3.91B0.543.14 million shs3.61 million shsARWRArrowhead Pharmaceuticals$27.73+2.1%$19.00$9.57▼$29.34$3.83B12.03 million shs2.39 million shsMIRMMirum Pharmaceuticals$77.69+0.4%$60.08$36.86▼$78.10$3.90B0.92527,243 shs604,085 shsPHGUFPharming Group$1.50$1.20$0.75▼$1.50$1.01B0.63918 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.67%-4.87%-0.61%-21.28%+0.98%ARWRArrowhead Pharmaceuticals-6.57%+23.33%+65.47%+60.11%+22.28%MIRMMirum Pharmaceuticals+1.75%+4.77%+29.05%+58.00%+88.21%PHGUFPharming Group0.00%+15.38%+31.58%+26.58%+98.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.39-0.2%$17.63$13.50▼$25.67$3.91B0.543.14 million shs3.61 million shsARWRArrowhead Pharmaceuticals$27.73+2.1%$19.00$9.57▼$29.34$3.83B12.03 million shs2.39 million shsMIRMMirum Pharmaceuticals$77.69+0.4%$60.08$36.86▼$78.10$3.90B0.92527,243 shs604,085 shsPHGUFPharming Group$1.50$1.20$0.75▼$1.50$1.01B0.63918 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.67%-4.87%-0.61%-21.28%+0.98%ARWRArrowhead Pharmaceuticals-6.57%+23.33%+65.47%+60.11%+22.28%MIRMMirum Pharmaceuticals+1.75%+4.77%+29.05%+58.00%+88.21%PHGUFPharming Group0.00%+15.38%+31.58%+26.58%+98.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6768.80% UpsideARWRArrowhead Pharmaceuticals 3.00Buy$43.1455.58% UpsideMIRMMirum Pharmaceuticals 3.13Buy$74.13-4.59% DownsidePHGUFPharming Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHGUF, ADMA, ARWR, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $89.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy8/7/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetMarket Outperform$79.00 ➝ $81.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$77.00 ➝ $82.008/7/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$73.00 ➝ $80.007/28/2025ARWRArrowhead PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$474.17M8.25$0.53 per share31.17$1.48 per share11.07ARWRArrowhead Pharmaceuticals$3.55M1,079.99N/AN/A$1.54 per share18.01MIRMMirum Pharmaceuticals$336.89M11.59N/AN/A$4.70 per share16.53PHGUFPharming Group$297.20M3.39N/AN/A$0.33 per share4.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8619.0623.75N/A44.06%41.01%28.47%11/6/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)PHGUFPharming Group-$11.84MN/A0.00∞N/A-2.19%-3.31%-1.78%11/6/2025 (Estimated)Latest PHGUF, ADMA, ARWR, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APHGUFPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78ARWRArrowhead Pharmaceuticals0.394.874.87MIRMMirum Pharmaceuticals1.213.132.97PHGUFPharming Group0.502.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ARWRArrowhead Pharmaceuticals62.61%MIRMMirum PharmaceuticalsN/APHGUFPharming GroupN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%ARWRArrowhead Pharmaceuticals4.30%MIRMMirum Pharmaceuticals22.87%PHGUFPharming GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million229.80 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableMIRMMirum Pharmaceuticals14050.24 million38.75 millionOptionablePHGUFPharming Group382671.07 millionN/ANot OptionablePHGUF, ADMA, ARWR, and MIRM HeadlinesRecent News About These CompaniesPharming Group (OTCMKTS:PHGUF) Hits New 52-Week High - Time to Buy?September 4, 2025 | marketbeat.comPharming Group Appoints Kenneth Lynard as CFO Amid Strong Financial PerformanceSeptember 2, 2025 | tipranks.comPharming Group (OTCMKTS:PHGUF) Reaches New 1-Year High - What's Next?August 21, 2025 | marketbeat.comPharming Group NV (OTCMKTS:PHGUF) Sees Significant Increase in Short InterestAugust 19, 2025 | marketbeat.comPharming Group to participate in August investor conference | PHARM Stock NewsAugust 4, 2025 | gurufocus.comPharming Group’s Strong Financial Performance and Strategic Developments Justify Buy RatingAugust 1, 2025 | tipranks.comPharming Group reports second quarter and first half 2025 financial results and provides ...July 31, 2025 | gurufocus.comPharming Group to report second quarter and first half 2025 financial results and provide business update on July 31July 17, 2025 | manilatimes.netMPharming Group to report second quarter and first half 2025 financial results and provide ...July 17, 2025 | gurufocus.comPharming Group (PHGN.DU)June 26, 2025 | sg.finance.yahoo.comPharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of ShareholdersJune 11, 2025 | finanznachrichten.dePharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...May 9, 2025 | uk.finance.yahoo.comPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)April 25, 2025 | finance.yahoo.comPharming announces positive recommendation from NICE for JoenjaApril 24, 2025 | finance.yahoo.comPharming Group to report first quarter 2025 financial results on May 8April 24, 2025 | finance.yahoo.comPharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDSApril 23, 2025 | finanznachrichten.deNICE Recommends Pharming Group's Joenja for Activated Phosphoinositide 3-Kinase Delta SyndromeApril 23, 2025 | precisionmedicineonline.comPPharming Group announces the filing of its 2024 Annual Report and Form 20-FApril 3, 2025 | finance.yahoo.comPharming Group (PHAR) Receives a Buy from H.C. WainwrightMarch 21, 2025 | markets.businessinsider.comPharming price target raised to $39 from $30 at OppenheimerMarch 14, 2025 | markets.businessinsider.comPharming Group N.V.: Pharming Group reports on results of the 2025 Extraordinary General Meeting of ShareholdersMarch 4, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025The Quiet Before the Catalyst: Vertical Aerospace's Next MoveBy Jeffrey Neal Johnson | September 9, 2025PHGUF, ADMA, ARWR, and MIRM Company DescriptionsADMA Biologics NASDAQ:ADMA$16.39 -0.03 (-0.18%) Closing price 04:00 PM EasternExtended Trading$16.52 +0.13 (+0.76%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Arrowhead Pharmaceuticals NASDAQ:ARWR$27.73 +0.56 (+2.06%) Closing price 04:00 PM EasternExtended Trading$27.84 +0.11 (+0.38%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Mirum Pharmaceuticals NASDAQ:MIRM$77.69 +0.30 (+0.39%) Closing price 04:00 PM EasternExtended Trading$78.85 +1.16 (+1.49%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Pharming Group OTCMKTS:PHGUF$1.50 0.00 (0.00%) As of 09/8/2025Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
